These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 2574447)
21. Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. Diana M; Collu M; Mura A; Gessa GL Eur J Pharmacol; 1992 Feb; 211(3):415-9. PubMed ID: 1352256 [TBL] [Abstract][Full Text] [Related]
22. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans. Kistrup K; Gerlach J Pharmacol Toxicol; 1987 Sep; 61(3):157-61. PubMed ID: 2891133 [TBL] [Abstract][Full Text] [Related]
23. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390. Hess EJ; Creese I Psychopharmacol Bull; 1986; 22(3):605-12. PubMed ID: 2879304 [No Abstract] [Full Text] [Related]
24. Tardive dyskinesia: a role for the endogenous opioid system. Sandyk R Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480 [TBL] [Abstract][Full Text] [Related]
25. Tardive dyskinesia and the behavioral consequences of chronic neuroleptic treatment. Gualtieri CT; Guimond M Dev Med Child Neurol; 1981 Apr; 23(2):255-9. PubMed ID: 6111511 [No Abstract] [Full Text] [Related]
26. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Diamond BI; Borison RL Psychopharmacol Bull; 1986; 22(3):900-5. PubMed ID: 2879312 [No Abstract] [Full Text] [Related]
27. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. Hess EJ; Albers LJ; Le H; Creese I J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223 [TBL] [Abstract][Full Text] [Related]
28. Effect of selective D1 and D2 dopamine receptor antagonists and agonists in Cebus monkeys: implications for acute and tardive dyskinesias. A preliminary report. Gerlach J; Kistrup K; Korsgaard S Psychopharmacol Ser; 1987; 3():236-42. PubMed ID: 3547396 [No Abstract] [Full Text] [Related]
29. Neuroleptic-induced supersensitivity psychosis. Chouinard G; Jones BD; Annable L Am J Psychiatry; 1978 Nov; 135(11):1409-10. PubMed ID: 30291 [No Abstract] [Full Text] [Related]
31. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Baldessarini RJ; Tarsy D Annu Rev Neurosci; 1980; 3():23-41. PubMed ID: 6106450 [No Abstract] [Full Text] [Related]
32. Behavioral effects of clozapine and dopamine receptor subtypes. Josselyn SA; Miller R; Beninger RJ Neurosci Biobehav Rev; 1997 Sep; 21(5):531-58. PubMed ID: 9353791 [TBL] [Abstract][Full Text] [Related]
33. Swallowing, tardive dyskinesia and anticholinergics. Craig TJ; Richardson MA Am J Psychiatry; 1982 Aug; 139(8):1083. PubMed ID: 6124138 [No Abstract] [Full Text] [Related]
34. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine. Sprah L; Zivin M; Sket D J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846 [TBL] [Abstract][Full Text] [Related]
35. Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Chouinard G; Steinberg S Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):571-8. PubMed ID: 6131490 [TBL] [Abstract][Full Text] [Related]